Clinical Trials

Study Title:
A First in human, Phase 1 Study to Evaluate the Safety of TTX 080, an HLA G Antagonist, in Subjects With Advanced Solid Tumors

For more information about the trial above please contact the study team:

Principal Investigator, John Kaczmar, at, or please call +1 843-792-6691.

Study Coordinator, Carly Fecio, at

Trial opened at the following institutions: Medical University of South Carolina